报告人：赖秀兰（中国人民大学）

时  间：5月11日晚上19:30

地  点：腾讯会议ID：5799224321（无密码）

内容摘要:

There has been much progress in recent years in developing checkpoint inhibitors, primarily PD-1 antibodies and PD-L1 antibodies. However, because of lack of tumor-infiltrating effector T cells, many patients in clinical trials do not respond to checkpoint inhibitor treatment. It was recently suggested that the combination of an immune checkpoint inhibitor and another anti-tumor drug, such as a chemotherapy drug or radiotherapy, may function synergistically to induce more effective antitumor immune responses. The questions in the design of cancer clinical trials with combination of two drugs includes in which proportion (dosage) and in which order to administer the drugs. In this talk, I will address the scheduling question by mathematical modeling approaches.

We considered the combination therapies of cancer with a checkpoint inhibitor and a cancer vaccine (or anti-VEGF) using mathematical models. We use mathematical models to explore the efficacy (synergistic or antagonistic) of the two drugs and the appropriate dosage and timing of the combination treatment.

个人简介：

赖秀兰，中国人民大学数学科学研究院副教授，2014年博士毕业于加拿大西安大略大学应用数学系，2014-2018年期间在中国人民大学数学科学研究院和美国俄亥俄州立大学生物数学所从事博士后研究，主要从事生物医学相关问题预测模型的数学建模、理论分析、数值模拟等方面研究，主题包括关于癌症诊断和治疗的数学建模研究、细胞内物质传输与神经系统疾病的多尺度模型研究、感染者体内病毒动力学研究等。在PNAS, BMC System Biology, Science China Mathematics, Journal of Differential Equations, BMC System Biology, Journal of Theoretical Biology, Journal of the Royal Society Interface, SIAM Journal of Applied Math等SCI期刊发表20余篇论文。作为课题负责人主持过两项国家自然科学基金项目。

联系人：周达